ID	Description	GeneRatio	BgRatio	pvalue	p.adjust	qvalue	geneID	Count
WP5095	Overview of proinflammatory and profibrotic mediators	40/643	73/6030	8.91593048951596e-21	4.31531035692572e-18	3.5100610558726e-18	6356/6357/6361/6362/6347/6364/6370/10344/6348/6351/9560/1437/1440/2919/3627/6373/284340/2920/2921/6374/6372/4283/3458/3586/3589/3605/29949/3552/3553/3557/51561/11009/3569/4312/4314/4318/5008/5196/6696/7124	40
WP5055	Burn wound healing	37/643	97/6030	6.89429652396297e-13	1.66841975879904e-10	1.35708784208534e-10	8038/6347/57124/1277/1278/2919/3579/2162/2200/3082/3383/3552/3553/3569/3624/3853/23643/440823/4312/4322/4313/4314/4318/64332/64127/5159/6282/6280/6423/6678/7042/7043/7076/7097/51311/3371/7124	37
WP5115	Network map of SARS-CoV-2 signaling pathway	55/643	190/6030	1.12093429919951e-12	1.80844066937521e-10	1.4709804487741e-10	59272/183/335/341/8542/684/715/838/6356/6347/6364/10344/6348/6351/1234/1051/629/3426/5199/1294/2919/3627/2920/2921/6374/6372/4283/3577/3579/84985/3091/10964/8519/10410/3458/3586/3605/8807/3552/3553/3569/3699/3726/116844/64386/114548/4939/5196/5743/6288/6289/6403/5054/6772/7124	55
WP2806	Complement system	30/643	75/6030	2.67141136584033e-11	3.2324077526668e-09	2.6292311863797e-09	133/335/715/717/720/722/728/27202/958/1604/22918/629/3426/5199/2162/2214/2219/2357/2769/3383/3687/3689/5648/5329/6401/6402/6403/710/6696/7097	30
WP4891	COVID-19 adverse outcome pathway	11/643	13/6030	1.19580341479727e-09	1.15753770552376e-07	9.4153784659827e-08	59272/183/6347/6348/1440/3627/3586/3553/3559/3569/7124	11
WP3624	Lung fibrosis	22/643	52/6030	3.54660268013127e-09	2.86092616197256e-07	2.32706912696333e-07	6356/6347/6348/6351/1232/1051/1215/1437/1440/2920/57105/2252/26585/3082/3553/3569/4313/4318/5328/6696/7076/7124	22
WP691	Tamoxifen metabolism	12/643	17/6030	7.33443464975196e-09	5.07123767211421e-07	4.12493016392065e-07	1545/1557/1558/1559/1565/1576/2326/2328/6783/6822/54657/7364	12
WP619	Type II interferon signaling	17/643	34/6030	9.92021707066291e-09	6.00173132775106e-07	4.88179103214201e-07	4261/3627/4283/2633/3383/3433/3458/3553/3659/9636/4843/5698/8651/9021/6688/6772/6890	17
WP5088	Prostaglandin signaling	15/643	28/6030	2.22522720418993e-08	1.18758586846626e-06	9.65978936073034e-07	834/6347/6348/2919/3627/4283/3458/3605/3552/3553/3569/4318/114548/9536/7124	15
WP2882	Nuclear receptors meta-pathway	59/643	268/6030	2.4536898108807e-08	1.18758586846626e-06	9.65978936073034e-07	5243/1244/64240/64241/51129/335/345/8553/330/874/6347/6364/1545/1555/1557/1559/1576/1551/1907/9982/2938/2939/1839/3082/3458/3589/3553/3726/23764/4199/8431/9971/9970/5142/5743/6286/6319/5272/6514/6515/11182/115584/159963/6527/200010/11254/340024/6532/23657/8140/5552/27286/2040/6822/7042/7056/7124/54657/7364	59
WP5039	SARS-CoV-2 innate immunity evasion and cell-specific immune response	23/643	63/6030	4.49504518108958e-08	1.97781987967942e-06	1.60875301217943e-06	59272/6347/6348/6351/1437/2919/3627/6373/284340/2920/2921/6374/6372/4283/3579/3433/8519/3586/3569/3902/5196/6772/7124	23
WP2865	IL1 and megakaryocytes in obesity	13/643	23/6030	8.51806125652873e-08	3.43561804013325e-06	2.79452185082609e-06	6347/1232/2205/1839/3383/3458/3553/4318/114548/7941/6280/7076/7097	13
WP455	GPCRs, class A rhodopsin-like	33/643	118/6030	1.0789543053975e-07	4.01702987547992e-06	3.26744056857218e-06	51554/134/27202/1230/2826/1232/1234/1237/10803/3577/3579/57105/1909/2151/2867/2357/2358/29909/2828/8111/8843/3274/3352/4543/64106/4888/53829/5031/5724/5737/5739/6752/56670	33
WP2328	Allograft rejection	25/643	76/6030	1.26362467069459e-07	4.36821510310792e-06	3.55309362453755e-06	5243/717/720/721/958/1604/941/1493/6373/4283/50943/10578/3002/3119/3134/3458/3586/3605/3552/3553/3559/120892/5551/6772/7124	25
WP5198	Inflammatory bowel disease signaling	16/643	35/6030	1.3537856724508e-07	4.36821510310792e-06	3.55309362453755e-06	50943/3458/3586/3594/3595/8807/3552/50615/51561/3569/4094/64127/6772/30009/7097/7124	16
WP129	Matrix metalloproteinases	13/643	24/6030	1.67857726278078e-07	5.07769621991185e-06	4.13018352815796e-06	4312/4319/4321/4322/4327/4313/10893/64386/4314/4316/4318/7076/7124	13
WP1533	Vitamin B12 metabolism	16/643	37/6030	3.49613211099284e-07	9.92757156084895e-06	8.0750582073891e-06	335/338/875/6347/8029/3383/3458/3553/3569/3949/6288/6289/5054/6648/6947/7124	16
WP3617	Photodynamic therapy-induced NF-kB survival signaling	15/643	33/6030	3.69207206808432e-07	9.92757156084895e-06	8.0750582073891e-06	597/330/1437/2920/3383/3552/3553/3569/4312/4313/4314/4318/5743/6401/7124	15
WP530	Cytokines and inflammatory response	11/643	19/6030	6.32470269335272e-07	1.55067236928869e-05	1.26131245348841e-05	1437/1440/2919/2920/3458/3586/3589/3552/3553/3569/7124	11
WP4754	IL-18 signaling pathway	51/643	239/6030	6.40773706317641e-07	1.55067236928869e-05	1.26131245348841e-05	321/467/330/6362/6347/6364/6348/6351/1051/9076/24146/6900/1277/1278/1281/2920/2921/338442/3383/3458/3586/8807/3553/3559/3569/3659/3801/4312/4322/4313/4314/4318/4688/64332/4843/8431/7941/5743/6004/8698/9021/6696/30009/7052/7076/7124/7127/4982/79931/7185/80149	51
WP15	Selenium micronutrient network	20/643	59/6030	1.35546299874625e-06	3.12401948282469e-05	2.54106847885262e-05	240/335/338/875/6347/1734/3383/3458/3553/3569/8564/8942/3949/5743/6288/6289/5054/6648/7124/7498	20
WP2877	Vitamin D receptor pathway	35/643	143/6030	1.49907536301884e-06	3.29796579864144e-05	2.68255591277055e-05	5243/240/248/768/838/875/958/634/1493/1594/1555/1559/1565/1576/168002/1673/50486/3091/3488/3726/5653/639/6273/6279/6280/10568/6696/6699/79689/412/6822/7042/7056/4982/54210	35
WP4462	Platelet-mediated interactions with vascular and circulating cells	10/643	17/6030	1.72104107791686e-06	3.6216690509207e-05	2.94585520888287e-05	6347/958/3383/3553/5196/6401/6403/7042/7043/7097	10
WP24	Peptide GPCRs	16/643	41/6030	1.85664427507339e-06	3.74423262139799e-05	3.04554806525196e-05	728/1230/2826/1232/1234/1237/10803/3577/3579/10663/1909/2357/2358/4888/6752/7253	16
WP4494	Selective expression of chemokine receptors during T-cell polarization	11/643	24/6030	1.26363733465183e-05	0.000238955165040007	0.000194365445247853	6348/6351/1230/1232/1234/1437/3458/3594/3595/7042/7043	11
WP702	Metapathway biotransformation Phase I and II	30/643	125/6030	1.28364344856202e-05	0.000238955165040007	0.000194365445247853	50515/9435/9469/1545/56603/1594/1555/1562/1557/1558/1559/1565/1576/1551/8529/260293/9420/2326/2327/2328/92292/2938/2939/9027/4837/6783/6822/54657/79799/7364	30
WP43	Oxidation by cytochrome P450	14/643	38/6030	1.79976890387078e-05	0.000322625240545725	0.00026242244446303	1545/56603/1594/1555/1562/1557/1558/1559/1565/1576/1551/8529/260293/9420	14
WP5218	Extrafollicular B cell activation by SARS-CoV-2	19/643	65/6030	2.8197265361688e-05	0.000487409872680608	0.000396457791175614	720/958/941/83416/29851/3433/8519/3458/3586/3569/9636/3687/3689/4094/639/6402/57823/30009/7124	19
WP5090	Complement system in neuronal development and plasticity	23/643	93/6030	7.98018723774571e-05	0.00133186573209273	0.00108333576294624	715/717/720/721/722/725/728/27202/843/1604/629/3426/5199/10584/2219/8547/3458/3687/3689/5648/710/7042/7043	23
WP2876	Pregnane X receptor pathway	11/643	29/6030	0.000106163778472039	0.00171277562601556	0.00139316677714184	5243/1244/1555/1557/1559/1576/1551/2939/27286/6822/54657	11
WP430	Statin inhibition of cholesterol production	10/643	25/6030	0.000130409386513682	0.00197244197101943	0.00160437863671437	64240/64241/335/337/338/341/345/3949/4547/6713	10
WP5092	Interactions of natural killer cells in pancreatic cancer	10/643	25/6030	0.000130409386513682	0.00197244197101943	0.00160437863671437	6347/6348/6351/1437/2214/3002/3458/4277/5551/7124	10
WP2289	Drug induction of bile acid pathway	7/643	13/6030	0.000146363870629648	0.00214667010256816	0.00174609529873966	5243/1244/1576/9971/9970/200931/6822	7
WP2431	Spinal cord injury	23/643	98/6030	0.000187367409138107	0.00260185404763782	0.00211634061291115	301/63827/6347/50515/1282/2919/3627/2920/2212/3383/3458/3552/3553/3569/10288/11025/4321/4318/4843/5320/5743/6403/7124	23
WP4341	Non-genomic actions of 1,25 dihydroxyvitamin D3	18/643	68/6030	0.000188150602618437	0.00260185404763782	0.00211634061291115	6347/958/1594/1673/10964/3458/3569/9636/5600/6300/64127/4939/91543/6258/6772/7097/51311/7124	18
WP1604	Codeine and morphine metabolism	6/643	10/6030	0.000206994484530816	0.00278292584758097	0.00226362389516156	5243/1244/1558/1565/1576/7364	6
WP2911	miRNA targets in ECM and membrane receptors	9/643	22/6030	0.000232951459367106	0.00304725692793728	0.00247863003707817	1278/1281/1282/1284/1290/50509/1291/1293/7058	9
WP545	Complement activation	8/643	18/6030	0.000264392403052228	0.00334027017479267	0.00271696617088399	715/717/720/721/1604/629/5199/5648	8
WP2875	Constitutive androstane receptor pathway	10/643	27/6030	0.000276055386346501	0.00334027017479267	0.00271696617088399	5243/1244/1555/1557/1559/1576/2939/9970/6822/54657	10
WP5113	Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway	10/643	27/6030	0.000276055386346501	0.00334027017479267	0.00271696617088399	59272/6347/2939/3553/3569/4312/4314/5593/23657/7124	10
WP117	GPCRs, other	12/643	37/6030	0.000291709293423429	0.00344359263455951	0.00280100836303883	27202/1234/3577/3579/1909/29933/11245/53831/59340/53829/5737/6752	12
WP176	Folate metabolism	14/643	48/6030	0.0003257657024386	0.00362896886243522	0.00295179285461238	335/338/875/6347/3383/3458/3553/3569/3949/6288/6289/5054/6648/7124	14
WP558	Complement and coagulation cascades	14/643	48/6030	0.0003257657024386	0.00362896886243522	0.00295179285461238	715/717/721/728/1604/629/3426/5648/5328/5329/5054/710/7056/7450	14
WP2880	Glucocorticoid receptor pathway	17/643	65/6030	0.000329906260221384	0.00362896886243522	0.00295179285461238	51129/8553/330/6347/6364/1907/9982/3589/8972/9970/5142/5743/6286/5272/5552/2040/7056	17
WP4559	Interactions between immune cells and microRNAs in tumor microenvironment	10/643	28/6030	0.000388962799587547	0.00418351100000828	0.00340285583732731	6347/29126/941/1493/3627/3559/8651/7042/7043/51311	10
WP5174	Ulcerative colitis signaling	7/643	15/6030	0.000453054287433224	0.0047669190242974	0.0038773982494285	50943/3458/3586/4094/64127/7097/7124	7
WP4329	miRNAs involvement in the immune response in sepsis	12/643	39/6030	0.000504063091890647	0.00508263617656402	0.00413420167471715	6348/6351/3002/3383/3586/3552/3569/3659/3934/407008/51311/7124	12
WP5097	CCL18 signaling pathway	12/643	39/6030	0.000504063091890647	0.00508263617656402	0.00413420167471715	467/1237/1278/1437/3091/440823/4313/4318/6615/6772/7291/652995	12
WP2848	Pluripotent stem cell differentiation pathway	11/643	34/6030	0.000533285170853305	0.0052675514835306	0.00428461125454642	3577/22943/2255/3082/3589/3569/3624/6469/7043/7472/7474	11
WP5094	Orexin receptor pathway	24/643	112/6030	0.000584293575074223	0.00565596180671848	0.00460054309637388	8553/2920/1734/1846/1959/1960/1839/3091/3383/3586/3553/3569/3726/3949/23764/4322/4314/64106/8013/5069/6401/6696/3371/7124	24
WP167	Eicosanoid synthesis	8/643	20/6030	0.000626840450832626	0.00594883878829394	0.0048387683923922	246/240/1800/5320/80339/5730/9536/5743	8
WP4969	RAS and bradykinin pathways in COVID-19	9/643	25/6030	0.000712928412539223	0.00663571830132661	0.00539747421639007	1636/59272/183/1576/3552/3553/5054/710/7124	9
WP299	Nuclear receptors in lipid metabolism and toxicity	9/643	26/6030	0.000988761171505268	0.00886222975941759	0.00720851224450234	5243/1244/64240/1594/1555/1559/1576/9971/9970	9
WP453	Inflammatory response pathway	9/643	26/6030	0.000988761171505268	0.00886222975941759	0.00720851224450234	958/941/1277/1278/1281/3458/3559/3568/3918	9
WP75	Toll-like receptor signaling pathway	19/643	84/6030	0.00107755532342108	0.00948248684610553	0.00771302757817196	6348/6351/958/941/3627/6373/4283/3553/3569/23643/1326/5600/6300/8503/6696/6772/7097/51311/7124	19
WP1433	Nucleotide-binding oligomerization domain (NOD) pathway	11/643	37/6030	0.00118302804713301	0.0102247424073639	0.00831677612082228	84674/834/838/50506/3553/4210/91662/114548/199713/64127/639	11
WP4724	Omega-9 fatty acid synthesis	6/643	13/6030	0.00127578144473038	0.0108329512149036	0.00881149141882112	2180/2182/54898/3992/9415/6319	6
WP465	Tryptophan metabolism	10/643	33/6030	0.00167544892828276	0.0138019041381976	0.0112264292033186	8854/316/1545/1562/1576/9420/3620/8942/4129/6999	10
WP5033	Genes associated with the development of rheumatoid arthritis	7/643	18/6030	0.00168246352097863	0.0138019041381976	0.0112264292033186	958/4261/1493/3559/23569/6583/7185	7
WP697	Estrogen metabolism	6/643	14/6030	0.00203316883238146	0.0164008952478771	0.0133404411107134	1545/1576/2938/412/6783/7364	6
WP716	Vitamin A and carotenoid metabolism	10/643	34/6030	0.00215135049387836	0.0170697317874939	0.0138844708319328	64240/64241/8854/1381/1382/56603/9227/29881/5948/6258	10
WP4522	Metabolic pathway of LDL, HDL and TG, including diseases	6/643	15/6030	0.00308657852901361	0.0240952259361708	0.0195989876035839	335/338/3949/9388/4547/255738	6
WP5044	Kynurenine pathway and links to cell senescence	7/643	20/6030	0.00338887456811986	0.0260351633487304	0.0211769271257615	3620/169355/3458/8564/8942/6999/7124	7
WP3942	PPAR signaling pathway	13/643	54/6030	0.00361500399108559	0.0273384676825848	0.0222370311293752	2180/2182/51129/335/345/126129/2172/9415/4199/4312/4973/6258/6319	13
WP4478	LTF danger signal response pathway	6/643	16/6030	0.00449935592265145	0.032502809948706	0.0264376923027752	3552/3553/3569/7097/7124/54210	6
WP4493	Cells and molecules involved in local acute inflammatory response 	6/643	16/6030	0.00449935592265145	0.032502809948706	0.0264376923027752	3383/3552/3569/3689/6403/7124	6
WP516	Hypertrophy model	6/643	16/6030	0.00449935592265145	0.032502809948706	0.0264376923027752	467/11072/1839/3458/3552/8013	6
WP4538	Regulatory circuits of the STAT3 signaling pathway	16/643	75/6030	0.00484272680639149	0.0344688202101982	0.0280368394054244	1271/1439/1441/2151/3595/3601/50615/3559/3568/3575/5600/6300/9180/5159/11122/9021	16
WP2884	NRF2 pathway	22/643	116/6030	0.00492914523515135	0.0345754535335254	0.0281235746444944	1244/874/2938/2939/1839/3082/23764/4199/6514/6515/11182/115584/159963/6527/200010/11254/340024/6532/23657/7042/54657/7364	22
WP4304	Oligodendrocyte specification and differentiation, leading to myelin components for CNS	7/643	22/6030	0.00616958868996363	0.0426582989420342	0.0346981378954345	2919/2920/3553/5354/6469/55553/7124	7
WP3967	miR-509-3p alteration of YAP1/ECM axis	6/643	17/6030	0.00633664565160889	0.0431962886673057	0.0351357371935022	1277/1281/1909/6678/7058/7291	6
WP4239	Epithelial to mesenchymal transition in colorectal cancer	24/643	134/6030	0.00717722952896581	0.0482469318336035	0.0392439158455148	9076/24146/51208/1282/1284/94234/11211/3091/3678/5600/6300/4313/4318/4854/4855/8503/6615/6678/7042/7043/7291/7480/7472/7474	24
WP3893	Development and heterogeneity of the ILC family	7/643	23/6030	0.00807011411363271	0.0535059620684689	0.0435215959408599	3458/3605/3553/51561/3569/30009/7124	7
WP4723	Omega-3 / omega-6 fatty acid synthesis	5/643	13/6030	0.00841872801447409	0.0550630318784522	0.0447881120542434	2180/2182/54898/3992/9415	5
WP497	Urea cycle and metabolism of amino groups	6/643	18/6030	0.00866373671692401	0.0551743233025161	0.0448786361790801	384/445/1373/2628/4942/5009	6
WP5149	Lipid metabolism in senescent cells	6/643	18/6030	0.00866373671692401	0.0551743233025161	0.0448786361790801	240/84647/50487/283748/7941/5743	6
WP3614	Photodynamic therapy-induced HIF-1 survival signaling	9/643	35/6030	0.00932099301610597	0.0585890989583804	0.0476562048943764	285/597/664/3091/4843/5743/5054/6515/7043	9
WP3929	Chemokine signaling pathway	26/643	152/6030	0.00966291869512892	0.0599596493390051	0.0487710066393821	6356/6361/6364/6370/10344/6348/6351/1230/2826/1232/1237/10803/3627/6373/2921/6374/4283/3579/10663/2268/2786/3055/4067/5196/8503/6772	26
WP4210	Tryptophan catabolism leading to NAD+ production	5/643	14/6030	0.0119662608934145	0.0723958784051576	0.0588865996596976	3620/8564/8942/10135/6999	5
WP5063	FOXP3 in COVID-19	5/643	14/6030	0.0119662608934145	0.0723958784051576	0.0588865996596976	941/50943/3559/3569/3575	5
WP4496	Signal transduction through IL1R	8/643	31/6030	0.0136466031731229	0.0815426658739689	0.0663265703281087	3552/3553/3557/3569/11213/7042/7043/7124	8
WP2374	Oncostatin M signaling pathway	13/643	64/6030	0.0158738621843259	0.0927361084362999	0.0754312843740239	6347/1051/3091/3726/3949/4312/4322/4314/5008/9180/5054/9021/6772	13
WP4389	Bile acids synthesis and enterohepatic circulation 	4/643	10/6030	0.0159030929756465	0.0927361084362999	0.0754312843740239	64240/64241/3949/6555	4
WP5109	Familial hyperlipidemia type 2	5/643	15/6030	0.0164061020756149	0.0945303976737808	0.0768907540887213	335/337/338/3949/255738	5
WP4718	Cholesterol metabolism with Bloch and Kandutsch-Russell pathways	10/643	45/6030	0.0178986304693507	0.101916907613715	0.0828989200685717	2180/2182/9023/54898/3992/9415/4597/6319/8435/6713	10
WP727	Monoamine transport	6/643	21/6030	0.0192061027420873	0.108090159618259	0.0879202255268133	183/3553/6532/6999/7124/4982	6
WP5122	Prostaglandin and leukotriene metabolism in senescence 	7/643	27/6030	0.0200820007510024	0.111720555902128	0.0908731794419225	246/240/3488/5600/5730/9536/5743	7
WP4747	Netrin-UNC5B signaling pathway	10/643	46/6030	0.0207615088484837	0.114188298666661	0.0928804343221642	249/6347/1003/1277/3383/3586/3552/54538/6401/7124	10
WP247	Small ligand GPCRs	5/643	16/6030	0.021818259417871	0.118652107396062	0.0965112835278977	4543/5724/5737/5739/8698	5
WP4136	Fibrin complement receptor 3 signaling pathway	8/643	35/6030	0.0278684891845128	0.148719163055569	0.120967740284434	6347/3627/2921/3569/3689/23643/4843/7124	8
WP3287	Overview of nanoparticle effects	5/643	17/6030	0.0282689318204801	0.148719163055569	0.120967740284434	1001/1282/3569/5743/7124	5
WP4790	FGF23 signaling in hypophosphatemic rickets and related disorders	5/643	17/6030	0.0282689318204801	0.148719163055569	0.120967740284434	249/1594/5251/142680/6696	5
WP5130	Th17 cell differentiation pathway	12/643	62/6030	0.0285830021764682	0.148754548961405	0.120996523078654	50943/3091/3458/3605/3553/50615/51561/3559/3569/9021/6772/30009	12
WP4197	Immune response to tuberculosis	6/643	23/6030	0.0297505654168104	0.151571301702487	0.123287661671879	3437/8519/3659/8651/6772/6890	6
WP5183	SARS-CoV-2 mitochondrial chronic oxidative stress and endothelial dysfunction	6/643	23/6030	0.0297505654168104	0.151571301702487	0.123287661671879	1636/59272/183/3569/114548/7124	6
WP364	IL6 signaling pathway	9/643	42/6030	0.030070083553493	0.151603337915527	0.123313719835596	183/3055/3569/3659/3726/639/9021/6772/7076	9
WP3611	Photodynamic therapy-induced AP-1 survival signaling	10/643	49/6030	0.0313382806078366	0.155793439586229	0.126721936505545	602/2252/1839/3458/3569/3726/5600/6300/4313/7124	10
WP4495	IL-10 anti-inflammatory signaling pathway 	4/643	12/6030	0.0315449526434926	0.155793439586229	0.126721936505545	3586/3552/3569/6772	4
WP2873	Aryl hydrocarbon receptor pathway	8/643	36/6030	0.0326064650912284	0.15940938489045	0.129663136035294	1545/2939/3458/3553/3726/8140/7124/54657	8
WP3932	Focal adhesion: PI3K-Akt-mTOR-signaling pathway	38/643	265/6030	0.0337437824540145	0.16331990707743	0.132843943555804	285/1277/1278/1281/1282/1284/1290/50509/84699/9586/1440/1441/2255/2252/2254/2786/3082/3091/3559/3575/3678/3687/3689/3918/10319/23566/4843/5008/9180/5159/5209/5228/6514/6515/6696/7058/3371/7450	38
WP236	Adipogenesis	19/643	115/6030	0.0341695146782147	0.163743020834217	0.133188103070894	183/1051/1271/56603/1959/3091/3569/10135/5008/80339/6258/6319/5054/8651/9021/6772/7124/7291/7480	19
WP474	Endochondral ossification	11/643	57/6030	0.0359086173249009	0.16691560271282	0.13576867206306	9507/249/50515/4256/4322/4318/5328/55553/6696/6772/7042	11
WP4808	Endochondral ossification with skeletal dysplasias	11/643	57/6030	0.0359086173249009	0.16691560271282	0.13576867206306	9507/249/50515/4256/4322/4318/5328/55553/6696/6772/7042	11
WP4721	Eicosanoid metabolism via lipooxygenases (LOX)	6/643	24/6030	0.0362110295141449	0.16691560271282	0.13576867206306	246/240/8529/57105/1800/2358	6
WP5036	Angiotensin II receptor type 1 pathway	6/643	24/6030	0.0362110295141449	0.16691560271282	0.13576867206306	59272/183/1277/1278/3091/3589	6
WP4298	Acute viral myocarditis	14/643	79/6030	0.0379871412217591	0.173450720295579	0.141084317943773	834/1232/1234/1604/941/3458/3586/3569/3689/4318/64127/8651/6772/7124	14
WP5108	Familial  hyperlipidemia type 1	4/643	13/6030	0.0418232747008342	0.187430231066702	0.152455211872437	51129/335/337/3949	4
WP554	ACE inhibitor pathway	4/643	13/6030	0.0418232747008342	0.187430231066702	0.152455211872437	1636/59272/183/1215	4
WP2895	Differentiation of white and brown adipocyte	5/643	19/6030	0.0444754372813227	0.19569192403782	0.159175249217366	1051/253738/3224/27129/51316	5
WP5066	FOXA2 pathway	5/643	19/6030	0.0444754372813227	0.19569192403782	0.159175249217366	1244/338/2938/2939/4547	5
WP3937	Microglia pathogen phagocytosis pathway	8/643	39/6030	0.0500177366166098	0.21809535605801	0.177398136506516	2207/2209/3055/3689/4067/4688/8503/54210	8
WP2849	Hematopoietic stem cell differentiation	9/643	46/6030	0.0508018388642597	0.219536517949122	0.178570373451439	4261/1437/1440/3552/3553/3569/4778/6688/23650	9
WP4719	Eicosanoid metabolism via cyclooxygenases (COX)	6/643	26/6030	0.0516576254811704	0.221259210025544	0.179971606240873	8529/5730/9536/5737/5739/5743	6
WP12	Osteoclast signaling	4/643	14/6030	0.0537660802238021	0.224334334726898	0.182472903844845	1513/8111/6696/4982	4
WP2879	Farnesoid X receptor pathway	4/643	14/6030	0.0537660802238021	0.224334334726898	0.182472903844845	1576/8431/9971/6822	4
WP3971	OSX and miRNAs in tooth development	4/643	14/6030	0.0537660802238021	0.224334334726898	0.182472903844845	249/22943/4854/4855	4
WP98	Prostaglandin synthesis and regulation	8/643	41/6030	0.0644438815006484	0.266588364498409	0.216842210357557	301/1909/3290/5730/9536/5737/5739/5743	8
WP5087	Malignant pleural mesothelioma	50/643	381/6030	0.0669621782208202	0.271651158186676	0.220960272209258	72/285/467/834/6347/6351/29126/1001/1003/1282/1284/1437/1440/115908/1496/2919/3627/6374/22943/2255/2252/2254/8061/11211/1839/3082/3091/3620/3586/3553/3569/3689/3918/10319/4313/4314/4318/114548/5159/5228/5328/6401/6423/6425/8140/6678/6772/7480/7472/7474	50
WP3	Transcriptional activation by NRF2 in response to phytochemicals	4/643	15/6030	0.0673515268231429	0.271651158186676	0.220960272209258	1051/2939/4094/23657	4
WP4842	Mammalian disorder of sexual development	4/643	15/6030	0.0673515268231429	0.271651158186676	0.220960272209258	84733/2254/5600/5730	4
WP5222	2q13 copy number variation syndrome	9/643	49/6030	0.0713689140025996	0.285475656010398	0.23220507905152	1437/3552/3553/3557/51561/3569/8651/9021/6772	9
WP4595	Urea cycle and associated pathways	5/643	22/6030	0.0773547729259006	0.306882869640458	0.249617645162095	445/1373/4843/4942/5009	5
WP2840	Hair follicle development: cytodifferentiation - part 3 of 3	11/643	65/6030	0.0806553817509741	0.317017244368664	0.257860916472119	22943/1959/94234/2619/3458/3488/5653/5650/4488/22822/7474	11
WP2815	Mammary gland development pathway - Involution (Stage 4 of 4)	3/643	10/6030	0.0819100954436211	0.317017244368664	0.257860916472119	1116/4318/9021	3
WP4877	Host-pathogen interaction of human coronaviruses - MAPK signaling	7/643	36/6030	0.0821656314232171	0.317017244368664	0.257860916472119	684/8519/10581/10410/3726/5600/6300	7
WP3413	NOTCH1 regulation of endothelial cell calcification	4/643	16/6030	0.0825292826249002	0.317017244368664	0.257860916472119	249/2702/4256/55553	4
WP706	Sudden infant death syndrome (SIDS) susceptibility pathways	19/643	128/6030	0.084427258203714	0.321754275359036	0.261714003880556	116/8553/720/721/1051/2328/3091/3586/3552/3553/3557/3569/3764/5354/6507/6532/6752/7124/11076	19
WP3668	Hypothesized pathways in pathogenesis of cardiovascular disease	5/643	23/6030	0.0905781639006478	0.342498682249325	0.278587444891795	285/2022/2200/4053/5054	5
WP5144	NRP1-triggered signaling pathways in pancreatic cancer 	9/643	52/6030	0.096449786277729	0.361873616731945	0.294346960978137	1003/1277/1278/3082/4313/4318/6615/7042/7043	9
WP5111	Familial hyperlipidemia type 4	4/643	17/6030	0.0992247751801064	0.36942147067055	0.300486363703318	335/337/3949/4547	4
WP5083	Neuroinflammation and glutamatergic signaling	17/643	115/6030	0.101580714822044	0.375305847128772	0.305272698621489	2893/2898/2906/116443/3458/3586/3552/3553/3569/29968/6507/6515/9021/6772/7042/7043/7124	17
WP3871	Valproic acid pathway	3/643	11/6030	0.104031212965073	0.375754530411158	0.305637656315296	116285/1555/1559	3
WP4583	Biomarkers for urea cycle disorders	3/643	11/6030	0.104031212965073	0.375754530411158	0.305637656315296	445/2628/5009	3
WP4707	Aspirin and miRNAs	3/643	11/6030	0.104031212965073	0.375754530411158	0.305637656315296	283120/4597/5743	3
WP3927	BMP signaling in eyelid development	4/643	18/6030	0.11734345623851	0.420698020884732	0.342194562442127	2255/2296/3625/6469	4
WP4545	Oxysterols derived from cholesterol	6/643	32/6030	0.118751673131102	0.42261624849598	0.343754843274242	134526/9023/1576/9420/3605/3638	6
WP3892	Development of pulmonary dendritic cells and macrophage subsets	3/643	12/6030	0.128193299738933	0.443182550526024	0.360483414303465	55509/1437/6688	3
WP5110	Familial hyperlipidemia type 3	3/643	12/6030	0.128193299738933	0.443182550526024	0.360483414303465	335/337/3949	3
WP5112	Familial hyperlipidemia type 5	3/643	12/6030	0.128193299738933	0.443182550526024	0.360483414303465	335/337/3949	3
WP5188	Retinol metabolism	3/643	12/6030	0.128193299738933	0.443182550526024	0.360483414303465	316/1551/9227	3
WP4756	Renin-angiotensin-aldosterone system (RAAS)	6/643	33/6030	0.132836865773532	0.454281676140709	0.369511411214931	1636/183/1215/84699/9586/3283	6
WP3646	Hepatitis C and hepatocellular carcinoma	8/643	48/6030	0.133280987628059	0.454281676140709	0.369511411214931	330/1284/3577/3091/3569/4312/4843/5743	8
WP4767	FGFR3 signaling in chondrocyte proliferation and terminal differentiation	5/643	26/6030	0.136556886958971	0.459715730089212	0.373931455096488	2254/5600/6300/6615/6772	5
WP3599	Transcription factor regulation in adipogenesis	4/643	19/6030	0.136774927960427	0.459715730089212	0.373931455096488	1051/3569/7124/7291	4
WP4879	Overlap between signal transduction pathways contributing to LMNA laminopathies	8/643	49/6030	0.145361392237905	0.485206302366525	0.394665413408178	1051/1513/3726/4129/6696/7042/4982/7480	8
WP4008	NO/cGMP/PKG mediated neuroprotection	6/643	34/6030	0.147673980012753	0.487729213764803	0.396717542296729	2906/3458/3553/4843/5593/7124	6
WP4655	Cytosolic DNA-sensing pathway	9/643	57/6030	0.148132633106252	0.487729213764803	0.396717542296729	834/843/6351/9560/3627/3553/3569/9636/81030	9
WP3869	Cannabinoid receptor signaling	5/643	27/6030	0.153801808416252	0.494321552533123	0.402079731725507	1557/1559/1576/5600/6300	5
WP1434	Osteopontin signaling	3/643	13/6030	0.154104307250362	0.494321552533123	0.402079731725507	4318/5328/6696	3
WP5178	Disorders of fructose metabolism	3/643	13/6030	0.154104307250362	0.494321552533123	0.402079731725507	229/3795/6514	3
WP4917	Proximal tubule transport	7/643	42/6030	0.15422015378616	0.494321552533123	0.402079731725507	5243/1244/6514/142680/6519/340024/11136	7
WP4787	Osteoblast differentiation and related diseases	14/643	98/6030	0.156611206355983	0.497908906708992	0.404997675313534	2255/2252/2254/11211/5600/6300/4854/4855/5288/8503/6772/7480/7472/7474	14
WP3645	NAD+ biosynthetic pathways	4/643	20/6030	0.157396823815032	0.497908906708992	0.404997675313534	952/3620/10135/6999	4
WP4786	Type I collagen synthesis in the context of osteogenesis imperfecta	5/643	28/6030	0.171894306353476	0.540239248539496	0.439429053835953	9509/1277/1278/60681/4982	5
WP262	Ebstein-Barr virus LMP1 signaling	4/643	21/6030	0.179078374688104	0.545534973147088	0.443736581028732	6364/9260/7124/7185	4
WP4141	PI3K/AKT/mTOR - vitamin D3 signaling	4/643	21/6030	0.179078374688104	0.545534973147088	0.443736581028732	941/3101/3586/6515	4
WP4564	Neural crest cell migration during development	6/643	36/6030	0.179432302927538	0.545534973147088	0.443736581028732	2047/2151/4313/4318/8503/7291	6
WP3935	Leptin-insulin signaling overlap	3/643	14/6030	0.181469278257606	0.545534973147088	0.443736581028732	8503/8651/9021	3
WP4337	ncRNAs involved in STAT3 signaling in hepatocellular carcinoma	3/643	14/6030	0.181469278257606	0.545534973147088	0.443736581028732	3589/3569/652995	3
WP4582	Cancer immunotherapy by CTLA4 blockade	3/643	14/6030	0.181469278257606	0.545534973147088	0.443736581028732	941/1493/8503	3
WP5061	Fatty acid transporters	3/643	14/6030	0.181469278257606	0.545534973147088	0.443736581028732	2180/2182/2172	3
WP4331	Neovascularisation processes	6/643	37/6030	0.196257436423894	0.586184797904405	0.476801031788272	3091/4318/4854/4855/7042/7043	6
WP2203	Thymic stromal lymphopoietin (TSLP) signaling pathway	7/643	45/6030	0.198423691461276	0.586184797904405	0.476801031788272	6356/3055/3559/3569/3575/4067/6772	7
WP5053	Development of ureteric collection system	8/643	53/6030	0.198624600942815	0.586184797904405	0.476801031788272	2296/80144/158326/341640/2674/80000/6469/7042	8
WP3591	Sleep regulation	4/643	22/6030	0.20168361952415	0.591605283937507	0.481210039566393	100/134/3569/5730	4
WP4258	lncRNA in canonical Wnt signaling and colorectal cancer	11/643	78/6030	0.205085171339548	0.597959174267117	0.486378275719665	467/22943/8061/11211/283120/5328/6423/6425/7480/7472/7474	11
WP272	Blood clotting cascade	3/643	15/6030	0.209998716116221	0.604996301191971	0.492102254558063	5328/5054/7450	3
WP698	Glucuronidation	3/643	15/6030	0.209998716116221	0.604996301191971	0.492102254558063	54657/79799/7364	3
WP4816	TGF-beta receptor signaling in skeletal dysplasias	8/643	54/6030	0.213050591750033	0.610156724301869	0.496299727901042	2022/2200/3458/3624/5054/6696/6772/7124	8
WP4357	NRF2-ARE regulation	4/643	23/6030	0.225074241760677	0.637052239837237	0.518176463025504	1051/2939/4094/23657	4
WP4585	Cancer immunotherapy by PD-1 blockade	4/643	23/6030	0.225074241760677	0.637052239837237	0.518176463025504	10538/29126/3458/80380	4
WP4241	Type 2 papillary renal cell carcinoma	5/643	31/6030	0.230479759321884	0.644042437299469	0.523862269573731	1513/112399/3091/7042/7043	5
WP4565	Neural crest cell migration in cancer	6/643	39/6030	0.231535917541545	0.644042437299469	0.523862269573731	2047/2151/4313/4318/8503/7291	6
WP534	Glycolysis and gluconeogenesis	6/643	39/6030	0.231535917541545	0.644042437299469	0.523862269573731	229/3099/3101/5313/6514/6515	6
WP3644	NAD+ metabolism	3/643	16/6030	0.239414739229603	0.658390532881409	0.535532969329376	952/10135/203447	3
WP4225	Pyrimidine metabolism and related diseases	3/643	16/6030	0.239414739229603	0.658390532881409	0.535532969329376	1373/5009/1890	3
WP3941	Oxidative damage response	6/643	40/6030	0.249877154409512	0.682957025260106	0.555515283704393	715/717/721/728/7124/7185	6
WP3298	Melatonin metabolism and effects	5/643	32/6030	0.25117014565351	0.682957025260106	0.555515283704393	1545/1557/1565/406938/4543	5
WP2324	AGE/RAGE pathway	9/643	65/6030	0.252993524523934	0.684071876366391	0.556422100393715	249/3091/3625/4322/4313/4316/4318/4843/6772	9
WP4830	GDNF/RET signaling axis	3/643	17/6030	0.269455445811638	0.724535754293517	0.589335302535396	2296/2674/26585	3
WP4900	Purinergic signaling	4/643	25/6030	0.273660966978797	0.731778497335567	0.595226528933237	134/5027/53829/5031	4
WP560	TGF-beta receptor signaling	7/643	50/6030	0.281063828599488	0.747444467264574	0.607969183899414	2022/3458/3624/5054/6696/6772/7124	7
WP2036	TNF-related weak inducer of apoptosis (TWEAK) signaling pathway	6/643	42/6030	0.287674331965653	0.759635029640452	0.617884952339123	330/6347/3569/4318/7124/7185	6
WP4846	SARS-CoV-2 and COVID-19 pathway	2/643	10/6030	0.289662244397036	0.759635029640452	0.617884952339123	59272/340024	2
WP3863	T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection	8/643	59/6030	0.290356364635297	0.759635029640452	0.617884952339123	1437/1493/29851/3458/3586/3937/1326/7124	8
WP4172	PI3K-Akt signaling pathway	33/643	280/6030	0.294265841069397	0.765724016546172	0.622837716807891	285/1277/1278/1282/1284/1291/1293/84699/9586/1440/1441/2255/2252/2254/2786/3082/3559/3569/3575/3678/3918/10319/23566/5008/9180/5159/5228/8503/6696/7058/7097/3371/7450	33
WP3877	MYD88 distinct input-output pathway	3/643	18/6030	0.299877843726264	0.776154419056213	0.631321776265819	3552/7097/51311	3
WP2371	Parkinson's disease pathway	5/643	35/6030	0.315549742647666	0.812372741709948	0.660781655936321	120892/5600/6300/9627/9246	5
WP2197	Endothelin pathways	4/643	27/6030	0.323769359460309	0.81715395409276	0.664670680362533	1909/2769/4852/5739	4
WP4961	STING pathway in Kawasaki-like disease and COVID-19	3/643	19/6030	0.330459640432359	0.81715395409276	0.664670680362533	2212/3553/114548	3
WP5181	Roles of ceramides in the development of insulin resistance	3/643	19/6030	0.330459640432359	0.81715395409276	0.664670680362533	2180/7124/7185	3
WP229	Irinotecan pathway	2/643	11/6030	0.33091358471525	0.81715395409276	0.664670680362533	1244/1576	2
WP3630	NAD metabolism, sirtuins and aging	2/643	11/6030	0.33091358471525	0.81715395409276	0.664670680362533	3091/10135	2
WP3930	EDA signaling in hair follicle development	2/643	11/6030	0.33091358471525	0.81715395409276	0.664670680362533	22943/6469	2
WP4271	Vitamin B12 disorders	2/643	11/6030	0.33091358471525	0.81715395409276	0.664670680362533	8029/6947	2
WP5052	Nephrogenesis	2/643	11/6030	0.33091358471525	0.81715395409276	0.664670680362533	8854/80000	2
WP3865	Novel intracellular components of RIG-I-like receptor (RLR) pathway	7/643	53/6030	0.334197159204989	0.821073223630532	0.667858602953064	843/3627/3458/9636/5600/6300/7124	7
WP2870	Extracellular vesicle-mediated signaling in recipient cells	4/643	28/6030	0.349081868311448	0.853311233650206	0.694080907753756	3082/7042/7043/7474	4
WP2018	RANKL/RANK signaling pathway	7/643	54/6030	0.352240264996153	0.853701043518487	0.694397977981544	1513/3383/4067/6688/6772/4982/7185	7
WP4336	ncRNAs involved in Wnt signaling in hepatocellular carcinoma	9/643	72/6030	0.359425551360822	0.853701043518487	0.694397977981544	22943/8061/11211/5328/6423/6425/7480/7472/7474	9
WP3640	Imatinib and chronic myeloid leukemia	3/643	20/6030	0.361000137482475	0.853701043518487	0.694397977981544	5243/5159/11040	3
WP4224	Purine metabolism and related disorders	3/643	20/6030	0.361000137482475	0.853701043518487	0.694397977981544	100/316/7498	3
WP4300	Extracellular vesicles in the crosstalk of cardiac cells	3/643	20/6030	0.361000137482475	0.853701043518487	0.694397977981544	3569/4318/6696	3
WP4963	p53 transcriptional gene network	10/643	81/6030	0.361588251903491	0.853701043518487	0.694397977981544	6347/126129/55332/3383/9636/4688/5268/5054/23657/7124	10
WP5098	T-cell activation SARS-CoV-2	10/643	81/6030	0.361588251903491	0.853701043518487	0.694397977981544	941/1493/29851/3458/3594/3595/3605/51561/3937/7124	10
WP2814	Mammary gland development pathway - Puberty (Stage 2 of 4)	2/643	12/6030	0.371457641710514	0.856121421847088	0.696366706765574	8061/7076	2
WP2881	Estrogen receptor pathway	2/643	12/6030	0.371457641710514	0.856121421847088	0.696366706765574	1545/8431	2
WP4211	Transcriptional cascade regulating adipogenesis	2/643	12/6030	0.371457641710514	0.856121421847088	0.696366706765574	1051/1959	2
WP4792	Purine metabolism	2/643	12/6030	0.371457641710514	0.856121421847088	0.696366706765574	100/7498	2
WP5171	Leukotriene metabolic pathway	2/643	12/6030	0.371457641710514	0.856121421847088	0.696366706765574	240/1800	2
WP4864	Host-pathogen interaction of human coronaviruses - apoptosis	3/643	21/6030	0.391320431281537	0.893530910649507	0.7267954775618	5600/6300/7124	3
WP4018	Clear cell renal cell carcinoma pathways	10/643	83/6030	0.391381307970445	0.893530910649507	0.7267954775618	229/3091/3099/3101/4199/5159/5313/29968/7042/7043	10
WP306	Focal adhesion	21/643	183/6030	0.394364304579001	0.896114194442425	0.728896713182834	330/1277/1278/1282/1284/1290/50509/2268/2318/3055/3082/3678/3918/10319/5159/5228/8503/6696/7058/3371/7450	21
WP2839	Hair follicle development: organogenesis - part 2 of 3	4/643	30/6030	0.399659624297022	0.899698875161668	0.731812482188917	3624/6469/6615/7474	4
WP4868	Type I interferon induction and signaling during SARS-CoV-2 infection	4/643	30/6030	0.399659624297022	0.899698875161668	0.731812482188917	59272/4939/6772/7097	4
WP2828	Bladder cancer	5/643	39/6030	0.403765306375388	0.900056977467791	0.732103761576672	1839/4312/4313/4318/1890	5
WP2435	Quercetin and Nf-kB / AP-1 induced apoptosis	2/643	13/6030	0.410976429794177	0.900056977467791	0.732103761576672	4312/5743	2
WP2813	Mammary gland development pathway - Embryonic development (Stage 1 of 4)	2/643	13/6030	0.410976429794177	0.900056977467791	0.732103761576672	249/7124	2
WP5176	Disorders of bile acid synthesis and biliary transport	2/643	13/6030	0.410976429794177	0.900056977467791	0.732103761576672	1244/9420	2
WP5192	Modulation of PI3K-Akt-mTOR signaling by bioactive sphingolipids	2/643	13/6030	0.410976429794177	0.900056977467791	0.732103761576672	56624/3091	2
WP692	Sulfation biotransformation reaction	2/643	13/6030	0.410976429794177	0.900056977467791	0.732103761576672	6783/6822	2
WP357	Fatty acid biosynthesis	3/643	22/6030	0.421263085769546	0.914310912611929	0.743697871502526	2180/2182/6319	3
WP3612	Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling	3/643	22/6030	0.421263085769546	0.914310912611929	0.743697871502526	1244/5600/6300	3
WP2406	Cardiac progenitor differentiation	4/643	31/6030	0.424723307997042	0.917705719065038	0.746459197325629	290/22943/3624/7070	4
WP69	T-cell receptor signaling pathway	10/643	86/6030	0.436267526261929	0.938459923158993	0.763340607354205	1234/29851/3601/3605/3552/3553/3569/3937/1326/3604	10
WP3925	Amino acid metabolism	9/643	77/6030	0.438502784945279	0.939094459794313	0.763856737631738	384/445/586/875/1373/3034/4942/5009/6999	9
WP5220	Metabolic reprogramming in pancreatic cancer	5/643	41/6030	0.447574311239828	0.94430581639612	0.768095640130816	3099/3949/4199/9122/8140	5
WP58	Monoamine GPCRs	2/643	14/6030	0.44922762171694	0.94430581639612	0.768095640130816	3274/3352	2
WP3845	Canonical and non-canonical Notch signaling	3/643	23/6030	0.450691412370876	0.94430581639612	0.768095640130816	4237/4854/4855	3
WP4483	Relationship between inflammation, COX-2 and EGFR	3/643	23/6030	0.450691412370876	0.94430581639612	0.768095640130816	4312/51365/5743	3
WP5046	NAD metabolism in oncogene-induced senescence and mitochondrial dysfunction-associated senescence	3/643	23/6030	0.450691412370876	0.94430581639612	0.768095640130816	3553/3569/10135	3
WP4666	Hepatitis B infection	15/643	134/6030	0.462039497523072	0.963909986211926	0.784041615579079	843/84699/9586/1959/1960/3569/5600/6300/4318/8503/6772/7042/7043/7097/7124	15
WP3945	TYROBP causal network in microglia	7/643	61/6030	0.478990873573343	0.976097598616174	0.793954984520333	10261/3687/3689/4094/4688/5341/6696	7
WP2864	Apoptosis-related network due to altered Notch3 in ovarian cancer	6/643	52/6030	0.484330485698516	0.976097598616174	0.793954984520333	602/79092/3575/9021/7124/7185	6
WP395	IL-4 signaling pathway	6/643	52/6030	0.484330485698516	0.976097598616174	0.793954984520333	1051/9046/5600/8651/9021/6772	6
WP4746	Thyroid hormones production and peripheral downstream signaling effects	9/643	80/6030	0.485603428989084	0.976097598616174	0.793954984520333	1734/50506/405753/4852/5593/6469/5172/7038/7253	9
WP197	Cholesterol biosynthesis pathway	2/643	15/6030	0.486032068732434	0.976097598616174	0.793954984520333	4597/6713	2
WP2855	Dopaminergic neurogenesis	2/643	15/6030	0.486032068732434	0.976097598616174	0.793954984520333	4929/6469	2
WP4159	GABA receptor signaling	2/643	15/6030	0.486032068732434	0.976097598616174	0.793954984520333	2557/2562	2
WP4872	MAP3K1 role in promoting and blocking gonadal determination	2/643	15/6030	0.486032068732434	0.976097598616174	0.793954984520333	2254/5600	2
WP5182	Pro-survival signaling of neuroprotectin D1	2/643	15/6030	0.486032068732434	0.976097598616174	0.793954984520333	330/7124	2
WP5205	Clock-controlled autophagy in bone metabolism	8/643	71/6030	0.490832601609046	0.981665203218091	0.798483658119979	8553/115908/1513/22943/3569/4982/7480/7474	8
WP1591	Heart development	4/643	34/6030	0.497983020340973	0.991867415000127	0.80678210789484	8553/2255/2296/6469	4
WP4673	Male infertility	11/643	100/6030	0.504553919906729	0.994562887000438	0.808974597081696	5243/338/56603/2346/4313/4318/4843/29968/6648/7124/10537	11
WP205	IL-7 signaling pathway	3/643	25/6030	0.507555853489893	0.994562887000438	0.808974597081696	3559/3575/6772	3
WP3613	Photodynamic therapy-induced unfolded protein response	3/643	25/6030	0.507555853489893	0.994562887000438	0.808974597081696	467/121506/6783	3
WP4950	16p11.2 distal deletion syndrome	3/643	25/6030	0.507555853489893	0.994562887000438	0.808974597081696	8519/5350/7185	3
WP2267	Synaptic vesicle pathway	5/643	44/6030	0.511539909295665	0.997199004147293	0.811118807201147	22999/246213/6507/6581/6532	5
WP2858	Ectoderm differentiation	13/643	120/6030	0.520150440930346	0.997199004147293	0.811118807201147	398/6347/1496/54898/57476/9687/152789/3801/3853/4061/6469/6781/4982	13
WP2011	SREBF and miR33 in cholesterol and lipid homeostasis	2/643	16/6030	0.521263115804267	0.997199004147293	0.811118807201147	3949/6319	2
WP368	Mitochondrial long chain fatty acid beta-oxidation	2/643	16/6030	0.521263115804267	0.997199004147293	0.811118807201147	2180/2182	2
WP4558	Overview of interferons-mediated signaling pathway	2/643	16/6030	0.521263115804267	0.997199004147293	0.811118807201147	3458/6772	2
WP4884	Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex	2/643	16/6030	0.521263115804267	0.997199004147293	0.811118807201147	3569/64386	2
WP3594	Circadian rhythm genes	17/643	159/6030	0.534294981328818	0.99999918490777	0.813396466192923	100/134/56938/8553/1960/50865/3569/4543/4547/10135/4843/5551/5593/60675/5730/5054/6532	17
WP3851	TLR4 signaling and tolerance	3/643	26/6030	0.53481240200668	0.99999918490777	0.813396466192923	3569/11213/7124	3
WP4829	mBDNF and proBDNF regulation of GABA neurotransmission	3/643	26/6030	0.53481240200668	0.99999918490777	0.813396466192923	2557/2562/8503	3
WP4658	Small cell lung cancer	10/643	93/6030	0.539038550418625	0.99999918490777	0.813396466192923	330/1282/1284/3918/10319/4843/8503/5743/6258/7185	10
WP254	Apoptosis	9/643	84/6030	0.546728510224735	0.99999918490777	0.813396466192923	330/834/843/3002/8739/3659/5551/7124/7185	9
WP3303	RAC1/PAK1/p38/MMP2 pathway	7/643	65/6030	0.54864413828015	0.99999918490777	0.813396466192923	285/9046/5600/6300/4313/4843/79931	7
WP100	Glutathione metabolism	2/643	17/6030	0.554837471803284	0.99999918490777	0.813396466192923	290/2938	2
WP3678	Amplification and expansion of oncogenic pathways as metastatic traits	2/643	17/6030	0.554837471803284	0.99999918490777	0.813396466192923	3371/7472	2
WP3874	Canonical and non-canonical TGF-B signaling	2/643	17/6030	0.554837471803284	0.99999918490777	0.813396466192923	26585/4017	2
WP4784	Proteoglycan biosynthesis	2/643	17/6030	0.554837471803284	0.99999918490777	0.813396466192923	9469/55790	2
WP4912	SARS coronavirus and innate immunity	2/643	17/6030	0.554837471803284	0.99999918490777	0.813396466192923	59272/6772	2
WP5074	Kallmann syndrome	2/643	17/6030	0.554837471803284	0.99999918490777	0.813396466192923	60675/9723	2
WP2643	Nanoparticle-mediated activation of receptor signaling	3/643	27/6030	0.561192782324976	0.99999918490777	0.813396466192923	1277/5600/6300	3
WP286	IL-3 signaling pathway	5/643	47/6030	0.572271875143287	0.99999918490777	0.813396466192923	1232/1439/3055/3568/4067	5
WP4150	Wnt signaling in kidney disease	3/643	28/6030	0.586646092006599	0.99999918490777	0.813396466192923	7480/7472/7474	3
WP4561	Cell migration and invasion through p75NTR	3/643	28/6030	0.586646092006599	0.99999918490777	0.813396466192923	4313/4318/7291	3
WP3859	TGF-beta signaling in thyroid cells for epithelial-mesenchymal transition	2/643	18/6030	0.586707425312911	0.99999918490777	0.813396466192923	6615/3371	2
WP4760	PKC-gamma calcium signaling pathway in ataxia	2/643	18/6030	0.586707425312911	0.99999918490777	0.813396466192923	2769/2893	2
WP5193	Cholesterol synthesis disorders	2/643	18/6030	0.586707425312911	0.99999918490777	0.813396466192923	4597/6713	2
WP399	Wnt signaling pathway and pluripotency	9/643	87/6030	0.590654687449043	0.99999918490777	0.813396466192923	8061/11211/3949/120892/4316/5328/7480/7472/7474	9
WP127	IL-5 signaling pathway	4/643	39/6030	0.609878411322305	0.99999918490777	0.813396466192923	1439/3568/4067/6772	4
WP408	Oxidative stress response	3/643	29/6030	0.611134455515944	0.99999918490777	0.813396466192923	3726/6648/7498	3
WP4698	Vitamin D-sensitive calcium signaling in depression	3/643	29/6030	0.611134455515944	0.99999918490777	0.813396466192923	775/1594/2906	3
WP1584	Type II diabetes mellitus	2/643	19/6030	0.616854223534153	0.99999918490777	0.813396466192923	6514/7124	2
WP325	Triacylglyceride synthesis	2/643	19/6030	0.616854223534153	0.99999918490777	0.813396466192923	56895/2819	2
WP4722	Glycerolipids and glycerophospholipids	2/643	19/6030	0.616854223534153	0.99999918490777	0.813396466192923	56895/80339	2
WP4657	22q11.2 copy number variation syndrome	9/643	90/6030	0.632482204278862	0.99999918490777	0.813396466192923	8854/9076/56603/2255/2296/4942/5625/6469/7450	9
WP4149	White fat cell differentiation	3/643	30/6030	0.634631658984713	0.99999918490777	0.813396466192923	1051/1959/7480	3
WP4313	Ferroptosis	6/643	61/6030	0.645119120586233	0.99999918490777	0.813396466192923	2180/2182/246/875/1803/23657	6
WP2878	PPAR-alpha pathway	2/643	20/6030	0.645282455317672	0.99999918490777	0.813396466192923	335/345	2
WP3580	Methionine de novo and salvage pathway	2/643	20/6030	0.645282455317672	0.99999918490777	0.813396466192923	51074/259307	2
WP2332	Interleukin-11 signaling pathway	4/643	41/6030	0.650095348306409	0.99999918490777	0.813396466192923	3383/3589/9021/6772	4
WP4844	Influence of laminopathies on Wnt signaling	3/643	31/6030	0.657121839447678	0.99999918490777	0.813396466192923	1051/6696/7480	3
WP382	MAPK signaling pathway	21/643	210/6030	0.658240177245058	0.99999918490777	0.813396466192923	775/994/1846/2255/2252/2254/2318/3310/3552/3553/120892/1326/5600/6300/22808/5159/283748/115727/7042/7043/7124	21
WP2359	Parkin-ubiquitin proteasomal system pathway	6/643	62/6030	0.661019052611328	0.99999918490777	0.813396466192923	834/3310/9627/10381/84617/9246	6
WP1423	Ganglio sphingolipid metabolism	1/643	10/6030	0.676473877910506	0.99999918490777	0.813396466192923	6482	1
WP2333	Trans-sulfuration pathway	1/643	10/6030	0.676473877910506	0.99999918490777	0.813396466192923	875	1
WP2436	Dopamine metabolism	1/643	10/6030	0.676473877910506	0.99999918490777	0.813396466192923	4129	1
WP3656	Interleukin-1 induced activation of NF-kB	1/643	10/6030	0.676473877910506	0.99999918490777	0.813396466192923	3552	1
WP5050	TCA cycle in senescence	1/643	10/6030	0.676473877910506	0.99999918490777	0.813396466192923	4199	1
WP5104	Acquired partial lipodystrophy / Barraquer-Simons syndrome	1/643	10/6030	0.676473877910506	0.99999918490777	0.813396466192923	629	1
WP5187	mRNA vaccine activation of dendritic cell and induction of IFN-1	1/643	10/6030	0.676473877910506	0.99999918490777	0.813396466192923	51311	1
WP4823	Genes controlling nephrogenesis	3/643	32/6030	0.678598241779859	0.99999918490777	0.813396466192923	2296/5159/6469	3
WP2586	Aryl hydrocarbon receptor pathway	4/643	43/6030	0.687458647195134	0.99999918490777	0.813396466192923	1545/135112/5743/7124	4
WP4539	Synaptic signaling pathways associated with autism spectrum disorder	4/643	43/6030	0.687458647195134	0.99999918490777	0.813396466192923	775/2906/116443/8503	4
WP4482	Vitamin D in inflammatory diseases	2/643	22/6030	0.697090521371405	0.99999918490777	0.813396466192923	3569/7124	2
WP410	Exercise-induced circadian regulation	4/643	44/6030	0.705050520985081	0.99999918490777	0.813396466192923	1051/50486/2674/10381	4
WP3679	Cell-type dependent selectivity of CCK2R signaling	1/643	11/6030	0.711029907230032	0.99999918490777	0.813396466192923	952	1
WP4788	Autosomal recessive osteopetrosis pathways	1/643	11/6030	0.711029907230032	0.99999918490777	0.813396466192923	29887	1
WP4919	Neuroinflammation	1/643	11/6030	0.711029907230032	0.99999918490777	0.813396466192923	4843	1
WP4947	Nitric oxide metabolism in cystic fibrosis	1/643	11/6030	0.711029907230032	0.99999918490777	0.813396466192923	4843	1
WP5191	Resolvin E1 and resolvin D1 signaling pathways promoting inflammation resolution	1/643	11/6030	0.711029907230032	0.99999918490777	0.813396466192923	2358	1
WP170	Nuclear receptors	3/643	34/6030	0.718521313294413	0.99999918490777	0.813396466192923	9970/4929/6258	3
WP2361	Gastric cancer network 1	2/643	23/6030	0.72055710318098	0.99999918490777	0.813396466192923	11082/6286	2
WP34	Ovarian infertility	2/643	23/6030	0.72055710318098	0.99999918490777	0.813396466192923	1051/2701	2
WP5064	7-oxo-C and 7-beta-HC pathways	2/643	23/6030	0.72055710318098	0.99999918490777	0.813396466192923	134526/3290	2
WP428	Wnt signaling	9/643	98/6030	0.731707884469091	0.99999918490777	0.813396466192923	22943/8061/11211/5328/6423/6425/7480/7472/7474	9
WP3527	Pre-implantation embryo	3/643	35/6030	0.736989924093154	0.99999918490777	0.813396466192923	366/55509/94234	3
WP2513	Nanoparticle triggered regulated necrosis	1/643	12/6030	0.741900113186352	0.99999918490777	0.813396466192923	7124	1
WP3876	BMP2-WNT4-FOXO1 pathway in primary endometrial stromal cell differentiation	1/643	12/6030	0.741900113186352	0.99999918490777	0.813396466192923	22943	1
WP4190	Mevalonate arm of cholesterol biosynthesis pathway	1/643	12/6030	0.741900113186352	0.99999918490777	0.813396466192923	4597	1
WP4504	Cysteine and methionine catabolism	1/643	12/6030	0.741900113186352	0.99999918490777	0.813396466192923	875	1
WP5173	Disorders of galactose metabolism 	1/643	12/6030	0.741900113186352	0.99999918490777	0.813396466192923	6514	1
WP1539	Angiogenesis	2/643	24/6030	0.742472433733018	0.99999918490777	0.813396466192923	3091/4318	2
WP26	S1P receptor signal transduction	2/643	24/6030	0.742472433733018	0.99999918490777	0.813396466192923	6300/8877	2
WP289	Myometrial relaxation and contraction pathways	12/643	131/6030	0.754348851574712	0.99999918490777	0.813396466192923	133/467/2786/3488/3553/3569/23764/5142/10268/6004/5999/8490	12
WP1528	Physiological and pathological hypertrophy of the heart	2/643	25/6030	0.762899962449811	0.99999918490777	0.813396466192923	183/5600	2
WP581	EPO receptor signaling	2/643	25/6030	0.762899962449811	0.99999918490777	0.813396466192923	8651/6772	2
WP3931	Embryonic stem cell pluripotency pathways	8/643	91/6030	0.768826857258442	0.99999918490777	0.813396466192923	2255/2252/2254/6300/5159/7480/7472/7474	8
WP304	Kit receptor signaling pathway	5/643	59/6030	0.7689405415509	0.99999918490777	0.813396466192923	3726/4067/6615/8651/6772	5
WP5037	Riboflavin and CoQ disorders	1/643	13/6030	0.769477086802366	0.99999918490777	0.813396466192923	55065	1
WP1422	Sphingolipid pathway	2/643	26/6030	0.781907259153406	0.99999918490777	0.813396466192923	56624/8877	2
WP241	One-carbon metabolism	2/643	26/6030	0.781907259153406	0.99999918490777	0.813396466192923	2346/2745	2
WP4875	Disruption of postsynaptic signaling by CNV	2/643	26/6030	0.781907259153406	0.99999918490777	0.813396466192923	2906/9378	2
WP2272	Pathogenic Escherichia coli infection	4/643	49/6030	0.782206759527401	0.99999918490777	0.813396466192923	9076/23643/10381/84617	4
WP710	DNA damage response (only ATM dependent)	9/643	103/6030	0.783755471765069	0.99999918490777	0.813396466192923	8061/3949/5288/8503/5328/6648/7480/7472/7474	9
WP4758	Nephrotic syndrome	3/643	38/6030	0.786660035949853	0.99999918490777	0.813396466192923	8542/1493/8029	3
WP3915	Angiopoietin-like protein 8 regulatory pathway	11/643	125/6030	0.793100763615178	0.99999918490777	0.813396466192923	64240/64241/1555/1576/1734/1326/5600/6300/5288/8503/6319	11
WP536	Calcium regulation in cardiac cells	11/643	125/6030	0.793100763615178	0.99999918490777	0.813396466192923	775/2701/2702/2709/10052/2786/3760/5350/6004/5999/8490	11
WP3969	H19 action Rb-E2F1 signaling and CDK-Beta-catenin activity	1/643	14/6030	0.794111661039707	0.99999918490777	0.813396466192923	283120	1
WP4584	Biomarkers for pyrimidine metabolism disorders	1/643	14/6030	0.794111661039707	0.99999918490777	0.813396466192923	1890	1
WP47	Hedgehog signaling pathway	1/643	14/6030	0.794111661039707	0.99999918490777	0.813396466192923	6469	1
WP2112	IL-17 signaling pathway	2/643	27/6030	0.79956441729968	0.99999918490777	0.813396466192923	1051/3605	2
WP2525	Trans-sulfuration and one-carbon metabolism	2/643	27/6030	0.79956441729968	0.99999918490777	0.813396466192923	875/29968	2
WP2533	Glycerophospholipid biosynthetic pathway	2/643	27/6030	0.79956441729968	0.99999918490777	0.813396466192923	2819/5320	2
WP5038	Mitochondrial immune response to SARS-CoV-2	2/643	27/6030	0.79956441729968	0.99999918490777	0.813396466192923	1636/59272	2
WP5085	Vasopressin-regulated water reabsorption	3/643	39/6030	0.801391838002148	0.99999918490777	0.813396466192923	398/84699/9586	3
WP1772	Apoptosis modulation and signaling	7/643	84/6030	0.806463901272958	0.99999918490777	0.813396466192923	597/330/664/834/843/8739/8794	7
WP4630	Measles virus infection	10/643	117/6030	0.814314817838581	0.99999918490777	0.813396466192923	3310/3552/3553/3559/3569/4939/8503/6504/6772/7097	10
WP3940	One-carbon metabolism and related pathways	3/643	40/6030	0.815261133109185	0.99999918490777	0.813396466192923	64902/586/6648	3
WP4222	Phosphodiesterases in neuronal function	3/643	40/6030	0.815261133109185	0.99999918490777	0.813396466192923	2906/10846/5142	3
WP4481	Resistin as a regulator of inflammation	2/643	28/6030	0.815942750014532	0.99999918490777	0.813396466192923	3569/7124	2
WP1946	Cori cycle	1/643	15/6030	0.816117346204512	0.99999918490777	0.813396466192923	6514	1
WP2291	Deregulation of Rab and Rab effector genes in bladder cancer	1/643	15/6030	0.816117346204512	0.99999918490777	0.813396466192923	201294	1
WP4962	Airway smooth muscle cell contraction	1/643	15/6030	0.816117346204512	0.99999918490777	0.813396466192923	952	1
WP5101	Congenital generalized lipodystrophy (CGL)	1/643	15/6030	0.816117346204512	0.99999918490777	0.813396466192923	3091	1
WP314	Fas ligand pathway and stress induction of heat shock proteins	3/643	41/6030	0.828300537172562	0.99999918490777	0.813396466192923	843/3552/7124	3
WP4290	Metabolic reprogramming in colon cancer	3/643	41/6030	0.828300537172562	0.99999918490777	0.813396466192923	229/3101/29968	3
WP49	IL-2 signaling pathway	3/643	41/6030	0.828300537172562	0.99999918490777	0.813396466192923	3559/9021/6772	3
WP3972	PDGFR-beta pathway	2/643	29/6030	0.831113734792205	0.99999918490777	0.813396466192923	5159/6772	2
WP4321	Thermogenesis	8/643	98/6030	0.834804728642018	0.99999918490777	0.813396466192923	2180/2182/126129/84699/9586/5600/6300/5593	8
WP22	IL-9 signaling pathway	1/643	16/6030	0.835774294897862	0.99999918490777	0.813396466192923	6772	1
WP4815	Glycosaminoglycan degradation	1/643	16/6030	0.835774294897862	0.99999918490777	0.813396466192923	3373	1
WP4970	Galanin receptor pathway	1/643	16/6030	0.835774294897862	0.99999918490777	0.813396466192923	3569	1
WP2572	Primary focal segmental glomerulosclerosis (FSGS)	5/643	65/6030	0.837373048368933	0.99999918490777	0.813396466192923	941/9076/22943/4311/5329	5
WP195	IL-1 signaling pathway	4/643	54/6030	0.842427910313039	0.99999918490777	0.813396466192923	6347/3552/3553/11213	4
WP143	Fatty acid beta-oxidation	2/643	30/6030	0.845148168778455	0.99999918490777	0.813396466192923	2180/2182	2
WP3858	Toll-like receptor signaling related to MyD88	2/643	30/6030	0.845148168778455	0.99999918490777	0.813396466192923	7097/51311	2
WP1982	Sterol regulatory element-binding proteins (SREBP) signaling	5/643	66/6030	0.846991035506922	0.99999918490777	0.813396466192923	3638/3949/4597/6319/6713	5
WP1971	Integrated cancer pathway	3/643	43/6030	0.852025129039528	0.99999918490777	0.813396466192923	994/4312/6772	3
WP5027	nsp1 from SARS-CoV-2 inhibits translation initiation in the host cell	1/643	17/6030	0.853332846341273	0.99999918490777	0.813396466192923	728689	1
WP5200	Dravet syndrome	1/643	17/6030	0.853332846341273	0.99999918490777	0.813396466192923	5600	1
WP2636	Common pathways underlying drug addiction	2/643	31/6030	0.85811550183575	0.99999918490777	0.813396466192923	72/2893	2
WP4871	Kisspeptin/kisspeptin receptor system in the ovary	2/643	31/6030	0.85811550183575	0.99999918490777	0.813396466192923	3283/4318	2
WP2064	Neural crest differentiation	5/643	68/6030	0.864817656544483	0.99999918490777	0.813396466192923	4488/4854/4855/6615/7291	5
WP4217	Ebola virus infection in host	10/643	124/6030	0.865423814225291	0.99999918490777	0.813396466192923	432/684/93978/2318/3119/3134/3678/8503/9021/6772	10
WP3670	Interactions between LOXL4 and oxidative stress pathway	1/643	18/6030	0.869016694637059	0.99999918490777	0.813396466192923	2252	1
WP4301	Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells	1/643	18/6030	0.869016694637059	0.99999918490777	0.813396466192923	22808	1
WP3995	Prion disease pathway	2/643	32/6030	0.870083319172809	0.99999918490777	0.813396466192923	10538/6688	2
WP4542	Leukocyte-intrinsic Hippo pathway functions	2/643	32/6030	0.870083319172809	0.99999918490777	0.813396466192923	50943/639	2
WP231	TNF-alpha signaling pathway	7/643	92/6030	0.873638785056029	0.99999918490777	0.813396466192923	330/6347/3569/1326/6401/7124/7185	7
WP4396	Nonalcoholic fatty liver disease	11/643	137/6030	0.878120262677675	0.99999918490777	0.813396466192923	6347/84701/3552/3553/3569/56901/9971/8503/5313/9021/7124	11
WP3529	Zinc homeostasis	2/643	33/6030	0.881116949303218	0.99999918490777	0.813396466192923	7780/169026	2
WP4874	CAMKK2 pathway	2/643	33/6030	0.881116949303218	0.99999918490777	0.813396466192923	3383/4094	2
WP4880	Host-pathogen interaction of human coronaviruses - interferon induction	2/643	33/6030	0.881116949303218	0.99999918490777	0.813396466192923	4939/6772	2
WP4142	Metabolism of spingolipids in ER and Golgi apparatus	1/643	19/6030	0.883025720809443	0.99999918490777	0.813396466192923	8877	1
WP4206	Hereditary leiomyomatosis and renal cell carcinoma pathway	1/643	19/6030	0.883025720809443	0.99999918490777	0.813396466192923	3091	1
WP5103	Progeria-associated lipodystrophy	1/643	19/6030	0.883025720809443	0.99999918490777	0.813396466192923	2200	1
WP5194	Synthesis of ceramides and 1-deoxyceramides	1/643	19/6030	0.883025720809443	0.99999918490777	0.813396466192923	8877	1
WP400	p38 MAPK signaling pathway	2/643	34/6030	0.891279176553769	0.99999918490777	0.813396466192923	6772/7042	2
WP4262	Breast cancer pathway	10/643	129/6030	0.894537480453003	0.99999918490777	0.813396466192923	2255/2252/2254/11211/4854/4855/8503/7480/7472/7474	10
WP2507	Nanomaterial induced apoptosis	1/643	20/6030	0.895538524256378	0.99999918490777	0.813396466192923	5551	1
WP3657	Hematopoietic stem cell gene regulation by GABP alpha/beta complex	1/643	20/6030	0.895538524256378	0.99999918490777	0.813396466192923	3002	1
WP4725	Sphingolipid metabolism overview	1/643	20/6030	0.895538524256378	0.99999918490777	0.813396466192923	8877	1
WP4288	MTHFR deficiency	1/643	21/6030	0.906714685471544	0.99999918490777	0.813396466192923	2906	1
WP4726	Sphingolipid metabolism: integrated pathway	1/643	21/6030	0.906714685471544	0.99999918490777	0.813396466192923	8877	1
WP4905	1q21.1 copy number variation syndrome	1/643	21/6030	0.906714685471544	0.99999918490777	0.813396466192923	2702	1
WP2637	Interleukin-1 (IL-1) structural pathway	3/643	49/6030	0.906844679031832	0.99999918490777	0.813396466192923	3552/1326/5600	3
WP4932	7q11.23 copy number variation syndrome	6/643	86/6030	0.908658122683829	0.99999918490777	0.813396466192923	9076/2200/3224/5313/9246/7472	6
WP2447	Amyotrophic lateral sclerosis (ALS)	2/643	36/6030	0.90922670601538	0.99999918490777	0.813396466192923	834/7124	2
WP3850	Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling	2/643	36/6030	0.90922670601538	0.99999918490777	0.813396466192923	3488/8744	2
WP623	Oxidative phosphorylation	2/643	36/6030	0.90922670601538	0.99999918490777	0.813396466192923	3002/56901	2
WP2037	Prolactin signaling pathway	5/643	75/6030	0.914029251307458	0.99999918490777	0.813396466192923	3659/4843/8651/9021/6772	5
WP3872	Regulation of apoptosis by parathyroid hormone-related protein	1/643	22/6030	0.916696788523932	0.99999918490777	0.813396466192923	597	1
WP4537	Hippo-Yap signaling pathway	1/643	22/6030	0.916696788523932	0.99999918490777	0.813396466192923	3627	1
WP4686	Leucine, isoleucine and valine metabolism	1/643	22/6030	0.916696788523932	0.99999918490777	0.813396466192923	586	1
WP4148	Splicing factor NOVA regulated synaptic proteins	2/643	37/6030	0.917123394366176	0.99999918490777	0.813396466192923	1600/2898	2
WP4249	Hedgehog signaling pathway	2/643	37/6030	0.917123394366176	0.99999918490777	0.813396466192923	2619/6469	2
WP500	Glycogen synthesis and degradation	2/643	38/6030	0.924371358722638	0.99999918490777	0.813396466192923	3099/3101	2
WP4541	Hippo-Merlin signaling dysregulation	7/643	101/6030	0.924919950601051	0.99999918490777	0.813396466192923	1001/1003/3627/3678/3687/3689/5159	7
WP3658	Wnt/beta-catenin signaling pathway in leukemia	1/643	23/6030	0.925612228766793	0.99999918490777	0.813396466192923	22943	1
WP3982	miRNA regulation of p53 pathway in prostate cancer	1/643	23/6030	0.925612228766793	0.99999918490777	0.813396466192923	5054	1
WP4906	3q29 copy number variation syndrome	3/643	52/6030	0.92669913275009	0.99999918490777	0.813396466192923	3091/8503/200931	3
WP2355	Corticotropin-releasing hormone signaling pathway	5/643	78/6030	0.929777607419931	0.99999918490777	0.813396466192923	8061/3283/3726/4929/6822	5
WP2526	PDGF pathway	2/643	39/6030	0.931018900383205	0.99999918490777	0.813396466192923	5159/6772	2
WP5124	Alzheimer's disease	18/643	226/6030	0.931211950281859	0.99999918490777	0.813396466192923	775/22943/11211/2906/3552/3553/3569/3800/4311/4843/8503/5743/7124/10381/84617/7480/7472/7474	18
WP585	Interferon type I signaling pathways	3/643	53/6030	0.93240278008908	0.99999918490777	0.813396466192923	8651/9021/6772	3
WP4521	Glycosylation and related congenital defects	1/643	24/6030	0.933574828550871	0.99999918490777	0.813396466192923	79644	1
WP4925	Unfolded protein response	1/643	24/6030	0.933574828550871	0.99999918490777	0.813396466192923	3553	1
WP4941	GPR143 in melanocytes and retinal pigment epithelium cells	1/643	24/6030	0.933574828550871	0.99999918490777	0.813396466192923	2769	1
WP4312	Rett syndrome causing genes	2/643	40/6030	0.937111414450259	0.99999918490777	0.813396466192923	3766/23221	2
WP1544	MicroRNAs in cardiomyocyte hypertrophy	5/643	80/6030	0.938796558112182	0.99999918490777	0.813396466192923	183/8503/5320/7124/7474	5
WP2059	Alzheimer's disease and miRNA effects	18/643	229/6030	0.939549269619889	0.99999918490777	0.813396466192923	775/22943/11211/2906/3552/3553/3569/3800/4311/4843/8503/5743/7124/10381/84617/7480/7472/7474	18
WP268	Notch signaling	2/643	41/6030	0.942691459438859	0.99999918490777	0.813396466192923	4854/4855	2
WP4806	EGFR tyrosine kinase inhibitor resistance	5/643	82/6030	0.946761888847722	0.99999918490777	0.813396466192923	3082/3569/22808/5159/8503	5
WP2817	Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4)	1/643	26/6030	0.947037442191148	0.99999918490777	0.813396466192923	1051	1
WP4534	Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms	2/643	42/6030	0.947798845081538	0.99999918490777	0.813396466192923	72/3689	2
WP4535	Envelope proteins and their potential roles in EDMD physiopathology	2/643	42/6030	0.947798845081538	0.99999918490777	0.813396466192923	7042/7043	2
WP61	Notch signaling pathway	3/643	57/6030	0.951360778458621	0.99999918490777	0.813396466192923	3091/4854/4855	3
WP3996	Ethanol effects on histone modifications	1/643	27/6030	0.952709481610051	0.99999918490777	0.813396466192923	8854	1
WP4856	Intracellular trafficking proteins involved in CMT neuropathy	1/643	27/6030	0.952709481610051	0.99999918490777	0.813396466192923	1959	1
WP5102	Familial partial lipodystrophy (FPLD)	1/643	27/6030	0.952709481610051	0.99999918490777	0.813396466192923	5396	1
WP5121	Sphingolipid metabolism in senescence	1/643	27/6030	0.952709481610051	0.99999918490777	0.813396466192923	8877	1
WP4255	Non-small cell lung cancer	4/643	71/6030	0.953529917360156	0.99999918490777	0.813396466192923	1381/1382/8503/6258	4
WP1403	AMP-activated protein kinase (AMPK) signaling	3/643	58/6030	0.9552568290087	0.99999918490777	0.813396466192923	126129/5209/8503	3
WP2038	Microtubule cytoskeleton regulation	2/643	44/6030	0.956741751050653	0.99999918490777	0.813396466192923	2151/11076	2
WP2583	T cell receptor and co-stimulatory signaling	1/643	28/6030	0.957774916113589	0.99999918490777	0.813396466192923	1493	1
WP183	Proteasome degradation	3/643	59/6030	0.958859585350542	0.99999918490777	0.813396466192923	3134/3458/5698	3
WP5072	Modulators of TCR signaling and T cell activation	3/643	59/6030	0.958859585350542	0.99999918490777	0.813396466192923	3937/1326/8651	3
WP2118	Arrhythmogenic right ventricular cardiomyopathy	3/643	60/6030	0.962189044254083	0.99999918490777	0.813396466192923	775/1496/3678	3
WP1601	Fluoropyrimidine activity	1/643	29/6030	0.96229852973221	0.99999918490777	0.813396466192923	1890	1
WP722	Serotonin HTR1 group and FOS pathway	1/643	29/6030	0.96229852973221	0.99999918490777	0.813396466192923	3352	1
WP4566	Translation inhibitors in chronically activated PDGFRA cells	2/643	46/6030	0.964207701945645	0.99999918490777	0.813396466192923	8503/11040	2
WP2034	Leptin signaling pathway	4/643	75/6030	0.965888971029542	0.99999918490777	0.813396466192923	3553/3557/9021/6772	4
WP2363	Gastric cancer network 2	1/643	30/6030	0.966338197351305	0.99999918490777	0.813396466192923	51316	1
WP3844	PI3K-AKT-mTOR signaling pathway and therapeutic opportunities	1/643	30/6030	0.966338197351305	0.99999918490777	0.813396466192923	8503	1
WP3888	VEGFA-VEGFR2 signaling pathway	33/643	409/6030	0.971034487534463	0.99999918490777	0.813396466192923	56999/301/6347/1003/79094/1558/22943/1847/1960/2022/24147/6624/1839/3383/6300/4319/4313/4688/4855/4929/8013/5228/5328/5329/5743/27289/57758/6401/9047/6648/6772/8794/81567	33
WP5224	2q37 copy number variation syndrome	6/643	104/6030	0.972235672051128	0.99999918490777	0.813396466192923	1293/6373/27128/3553/7124/54657	6
WP3998	Prader-Willi and Angelman syndrome	1/643	32/6030	0.973166985095232	0.99999918490777	0.813396466192923	2562	1
WP244	Alpha 6 beta 4 signaling pathway	1/643	33/6030	0.976043548713733	0.99999918490777	0.813396466192923	3918	1
WP3981	miRNA regulation of prostate cancer signaling pathways	1/643	33/6030	0.976043548713733	0.99999918490777	0.813396466192923	5159	1
WP422	MAPK cascade	1/643	33/6030	0.976043548713733	0.99999918490777	0.813396466192923	6300	1
WP185	Integrin-mediated cell adhesion	5/643	94/6030	0.977784529376427	0.99999918490777	0.813396466192923	11131/3678/3687/3689/6300	5
WP3286	Copper homeostasis	2/643	51/6030	0.97784578430488	0.99999918490777	0.813396466192923	79689/54739	2
WP313	Hepatocyte growth factor receptor signaling	1/643	34/6030	0.978612166051913	0.99999918490777	0.813396466192923	3082	1
WP4659	Gastrin signaling pathway	6/643	108/6030	0.979082533143915	0.99999918490777	0.813396466192923	330/9076/4316/8503/5743/5054	6
WP2795	Cardiac hypertrophic response	2/643	53/6030	0.981753959005425	0.99999918490777	0.813396466192923	5320/7124	2
WP4205	MET in type 1 papillary renal cell carcinoma	2/643	53/6030	0.981753959005425	0.99999918490777	0.813396466192923	3082/8503	2
WP4223	Ras signaling	10/643	161/6030	0.982480246231324	0.99999918490777	0.813396466192923	2786/22808/5159/8503/51365/84647/5320/50487/283748/115727	10
WP4216	Chromosomal and microsatellite instability in colorectal cancer 	3/643	70/6030	0.984095246461146	0.99999918490777	0.813396466192923	5743/7042/7043	3
WP35	G protein signaling pathways	4/643	85/6030	0.984701184088694	0.99999918490777	0.813396466192923	2769/2786/3760/5142	4
WP524	G13 signaling pathway	1/643	37/6030	0.984782351357265	0.99999918490777	0.813396466192923	398	1
WP51	Regulation of actin cytoskeleton	7/643	127/6030	0.986317552961537	0.99999918490777	0.813396466192923	2255/2252/2254/22808/5159/5288/8503	7
WP3584	MECP2 and associated Rett syndrome	2/643	56/6030	0.986391324109851	0.99999918490777	0.813396466192923	2893/6890	2
WP4263	Pancreatic adenocarcinoma pathway	4/643	87/6030	0.987025773322658	0.99999918490777	0.813396466192923	8503/6772/7042/7043	4
WP366	TGF-beta signaling pathway	7/643	130/6030	0.988935378721216	0.99999918490777	0.813396466192923	467/1278/50943/3726/4312/4321/3371	7
WP2853	Endoderm differentiation	6/643	118/6030	0.989949360064309	0.99999918490777	0.813396466192923	22943/1846/1847/3227/6772/30009	6
WP4155	Endometrial cancer	2/643	61/6030	0.991695181580666	0.99999918490777	0.813396466192923	1496/8503	2
WP4971	Phosphoinositides metabolism	1/643	44/6030	0.993127242169541	0.99999918490777	0.813396466192923	5288	1
WP2032	Thyroid stimulating hormone (TSH) signaling pathway	2/643	64/6030	0.99384216261829	0.99999918490777	0.813396466192923	6772/7253	2
WP4540	Hippo signaling regulation pathways	3/643	84/6030	0.995523929767904	0.99999918490777	0.813396466192923	1001/1003/5159	3
WP107	Translation factors	1/643	49/6030	0.99610698576809	0.99999918490777	0.813396466192923	728689	1
WP2380	Brain-derived neurotrophic factor (BDNF) signaling pathway	6/643	134/6030	0.997084349448107	0.99999918490777	0.813396466192923	249/1959/2562/4688/6696/6772	6
WP2857	Mesodermal commitment pathway	5/643	121/6030	0.997421538804439	0.99999918490777	0.813396466192923	8553/22943/2296/3624/6615	5
WP481	Insulin signaling	7/643	156/6030	0.998426066223382	0.99999918490777	0.813396466192923	1326/5600/6300/5288/8503/8651/9021	7
WP3680	Physico-chemical features and toxicity-associated pathways	1/643	58/6030	0.998602300860317	0.99999918490777	0.813396466192923	11211	1
WP4022	Pyrimidine metabolism	2/643	79/6030	0.998655355545982	0.99999918490777	0.813396466192923	956/1890	2
WP2261	Glioblastoma signaling pathways	2/643	82/6030	0.999012567225516	0.99999918490777	0.813396466192923	5159/5288	2
WP673	ErbB signaling pathway	2/643	83/6030	0.99910940145325	0.99999918490777	0.813396466192923	1839/8503	2
WP45	G1 to S cell cycle control	1/643	62/6030	0.999113936773308	0.99999918490777	0.813396466192923	84699	1
WP4685	Melanoma	1/643	63/6030	0.999209402365594	0.99999918490777	0.813396466192923	8503	1
WP437	EGF/EGFR signaling pathway	6/643	157/6030	0.999560790746321	0.99999918490777	0.813396466192923	9046/7837/9047/6456/6772/7291	6
WP4656	Joubert syndrome	1/643	71/6030	0.999682630464441	0.99999918490777	0.813396466192923	6469	1
WP23	B cell receptor signaling pathway	2/643	96/6030	0.999769968562106	0.99999918490777	0.813396466192923	27071/4067	2
WP179	Cell cycle	3/643	115/6030	0.999769978014044	0.99999918490777	0.813396466192923	994/7042/7043	3
WP138	Androgen receptor signaling pathway	1/643	85/6030	0.999935949286349	0.99999918490777	0.813396466192923	8431	1
WP2446	Retinoblastoma gene in cancer	1/643	86/6030	0.99994287689087	0.99999918490777	0.813396466192923	994	1
WP4549	Fragile X syndrome	1/643	101/6030	0.99998976554517	0.99999918490777	0.813396466192923	4318	1
WP4803	Ciliopathies	2/643	138/6030	0.999997415417485	0.99999918490777	0.813396466192923	122481/10309	2
WP4352	Ciliary landscape	5/643	201/6030	0.999998253974153	0.99999918490777	0.813396466192923	875/30845/3934/2040/339488	5
WP411	mRNA processing	1/643	123/6030	0.99999918490777	0.99999918490777	0.813396466192923	10772	1
